Belgia - inglise - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - exemestane 25 mg - film-coated tablet - 25 mg - exemestane 25 mg - exemestane

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - exemestane - coated tablet - 25 milligram(s) - aromatase inhibitors; exemestane

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

alvogen inc. - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane 25 mg - exemestane is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy [see clinical studies ( 14.1 )] . exemestane is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see clinical studies ( 14.2 )] . exemestane tablets are contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients. risk summary based on findings in animal studies and its mechanism of action, exemestane can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited human data from case reports are insufficient to inform a drug-associated risk. in animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increased incidence of abo

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

helm ag - exemestane - coated tablets - 25 milligram

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - exemestane - coated tablets - 25 milligram

Malta - inglise - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - exemestane - coated tablet - exemestane 25 mg - endocrine therapy

Kanada - inglise - Health Canada

pfizer canada ulc - exemestane - tablet - 25mg - exemestane 25mg - antineoplastic agents

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

originalis b.v. - exemestane - coated tablet - 25 milligram(s) - exemestane

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

alchemy health limited - exemestane 25mg - film coated tablet - 25 mg - active: exemestane 25mg excipient: colloidal silicon dioxide crospovidone hypromellose   macrogol 400 macrogol 6000 magnesium stearate mannitol microcrystalline cellulose polysorbate 80 purified talc sodium starch glycolate titanium dioxide - exemestane is indicated for: · the adjuvant treatment of postmenopausal women with oestrogen receptor positive or receptor unknown early breast cancer after initial adjuvant tamoxifen to reduce the risk of recurrence (distant and loco-regional) and contralateral breast cancer · the treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy · the third-line hormonal treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease progressed following treatment with anti-oestrogens and either non-steroidal aromatase inhibitors or progestins.

Iisrael - inglise - Ministry of Health

devries & co. ltd - exemestane - film coated tablets - exemestane 25 mg - exemestane - treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer following 2-3 years of initial adjuvant tamoxifen therapy.